Incyte (INCY) Tops Q1 EPS by 4c

Incyte (NASDAQ: INCY) reported Q1 EPS of ($0.96), $0.04 better than the analyst estimate of ($1.00). Revenue for the quarter came in at $384.08 million versus the consensus estimate of $358.27 million.

Cash, cash equivalents and marketable securities position As of March 31, 2017, cash, cash equivalents and marketable securities totaled $512 million as compared to $809 million as of December 31, 2016.

“The strong growth of Jakafi is very exciting as we continue to see more patients benefiting from treatment in both approved indications,” stated Hervé Hoppenot, Chief Executive Officer, Incyte. “We believe that our clinical portfolio is progressing well, with epacadostat moving rapidly into multiple pivotal programs and numerous other programs in or planned to enter potentially registration-enabling studies.”

For earnings history and earnings-related data on Incyte (INCY) click here.

You May Also Be Interested In

• Incyte (INCY) PT Raised to $105 at Truist Securities
• Creatd files Form S-1 and reports Q1 2026 financial results
• AMC Entertainment prices $200M stock offering to redeem senior notes